Contraindications: Do not use Uni-Pharma T3 if you have uncorrected adrenal insufficiency, acute myocardial infarction, thyrotoxicosis from any cause, or hypersensitivity to Liothyronine Sodium. Individuals with existing cardiac arrhythmias or uncontrolled hypertension must not use exogenous thyroid hormone without direct physician oversight.
Side_Effects: Elevated heart rate, increased perspiration, heat intolerance, and appetite fluctuation are the most commonly reported effects during the finisher phase. Insomnia and mild tremor may appear if doses advance too rapidly. Persistent tachycardia above 95 bpm or palpitations at rest require immediate dose reduction.
Monitoring: Track resting heart rate every morning throughout the protocol. Obtain a TSH, fT3, and fT4 panel at baseline before initiating the finisher, and repeat within two weeks of cessation to confirm hypothalamic-pituitary-thyroid axis recovery. Electrolyte status (sodium, potassium) should be checked given concurrent sodium-manipulation strategies common in contest prep.
PCT: No standard post-cycle therapy is required for T3 alone; however, thyroid axis recovery must be confirmed by returning TSH to pre-use reference range before considering any subsequent T3 protocol. Allow a minimum of eight to twelve weeks between finishing phases. If Liothyronine was run alongside suppressive AAS, those compounds' PCT requirements take priority and should be managed independently.
Lab Tested
